NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD
2.04
+0.11 (+5.7%)
The current stock price of OSTX is 2.04 USD. In the past month the price increased by 32.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
The current stock price of OSTX is 2.04 USD. The price increased by 5.7% in the last trading session.
The exchange symbol of OS THERAPIES INC is OSTX and it is listed on the NYSE Arca exchange.
OSTX stock is listed on the NYSE Arca exchange.
10 analysts have analysed OSTX and the average price target is 16.07 USD. This implies a price increase of 687.5% is expected in the next year compared to the current price of 2.04. Check the OS THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OS THERAPIES INC (OSTX) has a market capitalization of 44.19M USD. This makes OSTX a Nano Cap stock.
OS THERAPIES INC (OSTX) currently has 4 employees.
OS THERAPIES INC (OSTX) has a resistance level at 2.05. Check the full technical report for a detailed analysis of OSTX support and resistance levels.
The Revenue of OS THERAPIES INC (OSTX) is expected to grow by 26664% in the next year. Check the estimates tab for more information on the OSTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OSTX does not pay a dividend.
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.68).
The outstanding short interest for OS THERAPIES INC (OSTX) is 2.98% of its float. Check the ownership tab for more information on the OSTX short interest.
ChartMill assigns a technical rating of 5 / 10 to OSTX.
ChartMill assigns a fundamental rating of 3 / 10 to OSTX. OSTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.68. The EPS decreased by -128.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -196.54% | ||
ROE | -1341.48% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to OSTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 163.44% and a revenue growth 26664% for OSTX